Increase ACR Test Uptake with Digital Screening

Improve outcomes for people at risk for chronic kidney disease, close care gaps, reduce costs.

Funded Programmes Across the UK in partnership with NHSx, the Accelerated Access Collaborative and the National Institute for Health Research, have received funding to enable digital kidney health testing across the UK.

This nationally significant programme uses tried and tested technology to deliver a COVID safe service, which aims to improve outcomes in kidney health testing for people with diabetes and other cohorts at risk for chronic kidney disease. We are seeking immediate expressions of interest from PCNs, CCGs, STPs, and other providers which specialise in this area of healthcare. 

Smartphone-enabled testing has shown to increase uptake from 0% to 72% among consented untested patients, whilst minimising the traditional workload each practice has to take on to fulfill this care process.

Key Benefits

How It Works
Reach patients who are not engaging with traditional models of kidney testing by allowing them to test when it’s most convenient using their smartphone.
UK kit icon

Minuteful test kits measure ACR (albumin to creatine ratio) to identify early signs of kidney damage

Smartphone Urinalysis including app, cup, and dipstick

Patient scans the urine dipstick using a smartphone app, which guides them via a chatbot

Results transmitted to EMR

Results are analysed and uploaded to SystmOne or EMIS workflows in real time, for doctor review

Modality GP Partnership Testimonial Video
What Patients Say

found the test 'easy' or 'very
easy' to use

96% icon

preferred testing remotely
vs. testing at the clinic

would recommend this service
to a friend

The Smartphone as a Clinical-Grade Medical Device

The CKD early detection service increases adherence to annual urinary albumin to creatinine ratio (ACR) testing, which is known to be beneficial in the early detection and prevention of CKD, is recommended by NICE, and monitored by the National Diabetes Audit.

The test is built around the existing ACR point of care dipstick. It measures semi quantitative analysis of microalbumin (10 – 150 mg/L), creatinine (10 – 300mg/dL) and albumin to creatinine ratio (mg/g).

Results are expressed as ACR normal (<30mg/g), ACR abnormal (30-300mg/g) or ACR high abnormal (>300mg/g).

The product is CE marked, GDPR compliant, and follows industry standards for privacy and safety.

Call for Expressions of Interest

Subsidised deployments of the service are available to innovative, forward-thinking partners interested in empowering their patients and improving care through an evidence-based, time-saving, and patient-focused digital technology.

The availability of funding varies regionally ranging from 50% to 100% subsidies.  Please express your interest before 1pm on 11th June. Once submitted, we will be in touch to discuss the next steps towards releasing these benefits for your patient population at scale.

Please contact [email protected] with any questions.

By providing this information, you consent to receive relevant content from (You may opt out at any point.) For more information, visit our Privacy Policy.

By providing this information, you consent to receive relevant content from For more information, visit our Privacy Policy.
  1. Judith Shore, Michelle Green, Andrew Hardy & Deborah Livesey (2019): The compliance and cost-effectiveness of smartphone urinalysis albumin screening for people with diabetes in England, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2019.1650024